Altimmune
ALT
30 hedge funds and large institutions have $4.37M invested in Altimmune in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 6 closing their positions.
5% more capital invested
Capital invested by funds: $4.18M → $4.37M (+$194K)
0.08% more ownership
Funds ownership: 0.39% → 0.47% (+0.08%)
0% more funds holding
Funds holding: 30 → 30 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$870K |
| 2 |
Bank of New York Mellon
New York
|
+$147K |
| 3 |
LIM
Leavell Investment Management
Mobile,
Alabama
|
+$64.6K |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$59.6K |
| 5 |
JP Morgan Chase
New York
|
+$56.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$165K |
| 2 |
Squarepoint
New York
|
-$49K |
| 3 |
Millennium Management
New York
|
-$39.2K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$34.1K |
| 5 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$30.5K |
ALT Hedge Fund Activity: Q4 2017 in Review
30 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2017, worth a combined $4.37M — up 4.6% from $4.18M a quarter earlier.
Fund positioning in ALT was balanced in Q4 2017: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 10 trimmed.
The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $870K. The largest seller was Oxford Asset Management, exiting entirely with an estimated $165K sold.
- 30 institutional investors held Altimmune (ALT) as of Q4 2017, unchanged from Q3 2017.
- Funds reported $4.37M of Altimmune stock for Q4 2017, up 4.6% quarter-over-quarter.
- 6 funds opened new Altimmune positions in Q4 2017 and 6 closed out, a net change of 0 holders.
- The largest Altimmune buyer in Q4 2017 was Hudson Bay Capital Management, an estimated $870K added.
- The largest Altimmune seller in Q4 2017 was Oxford Asset Management, an estimated $165K sold.
Based on aggregated 13F filings for Q4 2017.